Baird analyst Michael Ha raised the firm’s price target on Astrana Health to $67 from $54 and keeps an Outperform rating on the shares. The firm called the company a Top Pick and believes the company is grossly undervalued and on the precipice of unlocking a wealth of growth.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH: